Skip to main content

Table 5 Adverse Reactions Categorized by Indication

From: 2015 Update on Acute Adverse Reactions to Gadolinium based Contrast Agents in Cardiovascular MR. Large Multi-National and Multi-Ethnical Population Experience With 37788 Patients From the EuroCMR Registry

  All RS CAD MYO/CMP Viability
Severe 2/37788 (0,01%) 2/18840 (0,01%) 0/14106 (0%) 0/4037 (0%)
Mild 43/37788 (0,11%) 7/18840 (0,04%) 22/14106 (0,16%) 9/4037 (0,22%)
All 45/37788 (0,12%) 9/18840 (0,05%) 22/14106 (0,16%) 9/4037 (0,22%)
  1. RS CAD, risk stratification in suspected coronary artery disease; MYO/CMP, work-up of suspected myocarditis or cardiomyopathy; Viability, work-up of myocardial viability in known coronary artery disease. See references 1- 4 for details